A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

Piritrexim is a lipid-soluble antifolate which, like methotrexate, has a potent capacity to inhibit dihydrofolate reductase. We performed a multicentre phase II study with piritrexim in patients with locally advanced or metastatic breast cancer. Twenty-four patients of which sixteen had received pri...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: de Vries, E. G., Gietema, J. A., Workman, P., Scott, J. E., Crawshaw, A., Dobbs, H. J., Dennis, I., Mulder, N. H., Sleijfer, D. T., Willemse, P. H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 1993
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC1968400/
https://ncbi.nlm.nih.gov/pubmed/8353055
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi